SFA Therapeutics is developing a next-generation oral immune tolerance therapy for psoriasis. Our investigational approach is designed to restore immune tolerance at its source, targeting the underlying immune dysfunction rather than broadly suppressing the immune system. Supported by early human results, our platform aims to deliver a more precise, patient-friendly treatment option for chronic inflammatory disease.